| [June 23, 2011] |
 |
2011 BIO International Convention Exhibitor Profiles
WASHINGTON --(Business Wire)--
2011
BIO International Convention, the largest global event for the
biotechnology industry, takes place June 27, 2011 through June 30, 2011
at the Walter E. Washington Convention Center in Washington DC.
Exhibitor profiles are listed below.
Business Wire is the official news
wire and online
press kit service for BIO 2011. Breaking news releases and exhibitor
press kits are available at TradeshowNews.com,
Business Wire's trade show, conference, and event news resource.
|
Company:
|
Ash Stevens
|
|
|
Booth:
|
1817
|
|
|
Web:
|
www.ashstevens.com
|
|
|
Ash Stevens, Inc. (ASI) is a full service Contract Pharmaceutical
Manufacturer offering comprehensive small-molecule drug substance
development and cGMP manufacturing services. ASI has extensive
experience developing and manufacturing Active Pharmaceutical
Ingredients (APIs). To date, ASI has received eleven FDA
manufacturing approvals for innovator APIs, including three Fast
Track manufacturing approvals for the active ingredients in the
oncology drugs Velcade®, Vidaza®, and Clolar®. Services offered by
Ash Stevens include: process development and scale-up; cGMP
manufacturing; the development and cGMP manufacture of highly potent
APIs using barrier-isolation technology; comprehensive analytical
capabilities; and regulatory support for all phases of drug
development and manufacturing.
|
|
|
|
|
|
|
|
|
|
Company:
|
Development Center for Biotechnology
|
|
Booth:
|
4413
|
|
|
Web:
|
www.dcb.org.tw
|
|
|
The Development Center for Biotechnology (DCB) of Taiwan is a
nonprofit organization founded in 1984 with the objective to advance
Taiwan's biotech-pharma industry by building infrastructure,
developing key technologies, and training talented workforces in
coordination with government, industry, and academic institutions.
In line with Taiwan's current biotech-pharma development policy,
which emphasizes value-addition and knowledge-basis, DCB positions
itself as a "Preclinical Value-Adding R&D Center for
Biopharmaceuticals". This role is to be fulfilled by devoting
concerted R&D efforts on protein, small molecule and botanical drug
leads in the preclinical stage of development and setting top
priorities for attaining Investigational New Drug approvals by
domestic and foreign regulatory agencies.
|
|
|
|
|
|
|
|
|
|
Company:
|
Elan Drug Technologies
|
|
|
Booth:
|
Partner Suite A129
|
|
|
Ticker Symbol & Exchange:
|
NYSE:ELN
|
|
|
Web:
|
www.elandrugtechnologies.com
|
|
|
Elan Drug Technologies is a global business that provides product
development and manufacturing services to the pharmaceutical market.
With over 40 years in the service business, we have proven expertise
in drug product development, process design and process
improvements. Building on our drug delivery and process development
expertise, we provide drug product optimization, scale-up and
manufacturing services in solid oral dosage forms. We offer our
clients unrivalled drug delivery expertise with a suite of
commercially launched, proprietary, technology-driven solutions.
Over 30 leading pharmaceutical companies are clients of ours, the
majority of which are long term strategic partners. For more
information see www.elandrugtechnologies.com
|
|
|
|
|
|
|
|
|
|
Company:
|
EStimME
|
|
|
Booth:
|
3737 - Hall A
|
|
|
Web:
|
www.EStimME.com
|
|
|
EStimME is a clinical-phase, medical device start-up company
developing a miniaturized implantable system for the treatment of
Tinnitus via electrical stimulation of the auditory (cochlear) nerve.
|
|
|
|
|
|
Tinnitus is the perception of sound, like "ringing in the ears", in
the absence of a physical source. Severe Tinnitus is a large, unmet
clinical need affecting around 1% of general population (~3 Million
people in the US).
|
|
|
|
|
|
EStimME's system consists of A tiny neurostimulator, remotely
powered and controlled by an external RF unit.
|
|
|
|
|
|
The implant has a self-expandable stent-like structure enabling easy
deployment and an atraumatic implantation through the ear canal.
|
|
|
|
|
|
|
|
|
|
Company:
|
Galileo Analytics
|
|
|
Booth:
|
4146
|
|
|
Web:
|
www.galileoanalytics.com
|
|
|
Galileo Analytics is a health data analytics company that uses
advanced analytics to transform your ability to understand clinical
health data. Our powerful analytical and visualization capabilities
provide the ability to analyze vast, complex data sets in minutes,
cutting weeks and months from data research timelines and providing
real-time answers to critical questions.
|
|
|
|
|
|
Galileo's tools empower you to quickly conduct analyses that inform
the most vital issues confronting biopharmaceutical companies:
|
|
• Inform licensing decisions through a greater understanding of the
treatment landscape
|
|
• Increase value and understanding of clinical trial data
|
|
|
• Fine-tune marketing strategies
|
|
|
|
• Improve post-marketing surveillance and health outcomes analysis
capabilities.
|
|
|
|
|
|
|
|
|
|
Company:
|
Life Science Tennessee
|
|
|
Booth:
|
4737
|
|
|
Web:
|
http://www.lifesciencetn.org/
|
|
|
Leaders from across Tennessee's diverse life science sector will
present the latest developments in Tennessee-based biotechnology,
biofuels, biopharma, biologistics and early-stage venture capital
initiatives at the Tennessee Pavilion (booth #4737) during this
month's BIO International Convention in Washington, D.C. Pavilion
participants include: Cool Springs Life Sciences Center, DDN,
Greater Memphis Chamber, Memphis Bioworks Foundation, Oak Ridge
National Laboratory and Tennessee Department of Economic and
Community Development. This year's Pavilion will highlight leading
voices from Tennessee's bioscience industry and will feature some of
the state's greatest assets in the life sciences space including
leading institutions Vanderbilt University, University of Tennessee
Research Foundation, Memphis Bioworks and Oak Ridge National
Laboratory.
|
|
|
|
|
|
|
|
|
|
Company:
|
NeuroVive Pharmaceutical
|
|
|
Booth:
|
4425
|
|
|
Ticker Symbol & Exchange:
|
NVP (Sweden: AktieTorget)
|
|
|
Web:
|
www.neurovive.com
|
|
|
NeuroVive Pharmaceutical is a Swedish drug development company whose
primary mission is to conduct research and develop pharmaceuticals
that protect nerve, cardiac and other cells undergoing
health-threatening traumas or ischemia. In addition to conducting or
supporting clinical trials of NeuroSTAT® for traumatic brain
injuries and CicloMulsion™ to protect cardiac tissue during
myocardial infarction, NeuroVive is researching and developing
variants of cyclophilin-D-inhibiting cyclosporins and new ways of
transporting these drugs across the blood-brain barrier to the CNS.
NeuroSTAT® is in a Phase II/III (adaptive) clinical study while
CicloMulsion™'s efficacy is being examined in a 1000-person Phase
III investigator-initiated study.
|
|
|
|
|
|
|
|
|
|
Company:
|
Sandia National Laboratories
|
|
|
Booth:
|
1359
|
|
|
Web:
|
www.sandia.gov
|
|
|
The Countering Biological Threats Program at Sandia National
Laboratories provides the science, technology, and technical policy
solutions for confronting the entire lifecycle of a biological
threat - from awareness to prevention, preparedness to detection,
and response to recovery. Sandia National Laboratories is a
multiprogram laboratory operated by Sandia Corporation, a wholly
owned subsidiary of Lockheed Martin (News - Alert) Corporation, for the U.S.
Department of Energy's National Nuclear Security Administration.
With main facilities in Albuquerque, N.M., and Livermore, Calif.,
Sandia has major R&D responsibilities in national security, energy
and environmental technologies, and economic competitiveness.
|
|
|
About Business Wire
Business
Wire, a Berkshire
Hathaway company, is utilized by tens of thousands of member
companies and organizations worldwide to functionally enhance and
communicate investor
relations and public
relations content to target audiences. As a recognized disclosure
service in the United States, Canada and a dozen European countries,
Business Wire facilitates the simultaneous flow of market-moving press
releases from corporations to financial markets and their audiences,
including regulatory authorities, media, investors, financial
information systems and consumer news services. Business Wire also
handles XBRL
tagging, document formatting and regulatory filing into EDGAR,
SEDAR, FSA and other systems.
Communications professionals turn to Business Wire to optimize and issue
press releases, photos and multimedia to news organizations,
journalists, trade publications, search engines, and individuals, with
full-text posting to web
sites, online services and databases. A range of distribution
options enables members to target by geography, industry, news theme
and audience demographics.
Founded in 1961, Business Wire has dual headquarters in San Francisco
and New York, with 31
bureaus in cities including Los Angeles, Chicago, Boston, Miami,
Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and
reciprocal offices throughout the world. Business Wire's patented NX
data platform supports XML, XHTML and XBRL code that enhances news
release interactivity, social media sharing and search
engine optimization. More information about Business Wire and its
services is located on its website at www.BusinessWire.com.
[ Back To TMCnet.com's Homepage ]
|
